Published in Lancet on December 25, 1976
Brain Changes by Rivastigmine According to Butyrylcholinesterase Alleles | NCT02063269
Alzheimer's disease: the challenge of the second century. Sci Transl Med (2011) 4.88
The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry (1999) 3.98
Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J (1978) 3.59
Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol (2009) 2.87
Neurocognitive aging: prior memories hinder new hippocampal encoding. Trends Neurosci (2006) 2.20
Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology (2008) 2.16
Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's Disease. Acta Neuropathol (1983) 1.91
Cnidarians as a source of new marine bioactive compounds--an overview of the last decade and future steps for bioprospecting. Mar Drugs (2011) 1.89
Neuropsychological syndromes in presenile dementia due to cerebral atrophy. J Neurol Neurosurg Psychiatry (1986) 1.83
Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes. Neurology (2010) 1.79
Dementia--the quiet epidemic. Br Med J (1978) 1.79
Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc Natl Acad Sci U S A (1986) 1.77
Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med (2014) 1.75
Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev Neurother (2008) 1.63
Genetically-directed, cell type-specific sparse labeling for the analysis of neuronal morphology. PLoS One (2008) 1.63
CFS hydroxylase cofactor levels in some neurological diseases. J Neurol Neurosurg Psychiatry (1980) 1.59
Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry (2007) 1.59
Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. Proc Natl Acad Sci U S A (2005) 1.51
The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm (Vienna) (2006) 1.50
Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain. Proc Natl Acad Sci U S A (1996) 1.45
Alzheimer's disease and mild cognitive impairment. Neurol Clin (2007) 1.39
The pharmacological landscape and therapeutic potential of serine hydrolases. Nat Rev Drug Discov (2012) 1.39
Diagnosis and treatment of dementia in the aged. West J Med (1981) 1.38
The cholinergic system and Parkinson disease. Behav Brain Res (2010) 1.38
Tetrahydroaminoacridine (THA) in Alzheimer's disease. BMJ (1989) 1.36
Estrogen therapy and cognition: a review of the cholinergic hypothesis. Endocr Rev (2009) 1.33
The p75 neurotrophin receptor promotes amyloid-beta(1-42)-induced neuritic dystrophy in vitro and in vivo. J Neurosci (2009) 1.31
Age and gene overexpression interact to abolish nesting behavior in Tg2576 amyloid precursor protein (APP) mice. Behav Brain Res (2010) 1.31
The role of G protein-coupled receptors in the pathology of Alzheimer's disease. Nat Rev Neurosci (2011) 1.30
Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease. J Psychiatry Neurosci (2004) 1.30
A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease. J Neurol Neurosurg Psychiatry (1985) 1.25
Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits. ACS Chem Neurosci (2013) 1.24
Cholinergic axons modulate GABAergic signaling among hippocampal interneurons via postsynaptic alpha 7 nicotinic receptors. J Neurosci (2007) 1.23
Single cell gene expression profiling in Alzheimer's disease. NeuroRx (2006) 1.22
Amyloid-β as a modulator of synaptic plasticity. J Alzheimers Dis (2010) 1.22
The basis for behavioural disturbances in dementia. J Neurol Neurosurg Psychiatry (1996) 1.22
Vascular disease and dementias: paradigm shifts to drive research in new directions. Alzheimers Dement (2012) 1.21
Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol (2011) 1.20
The noradrenergic system in Alzheimer and multi-infarct dementias. J Neurol Neurosurg Psychiatry (1982) 1.15
Tetrahydrobiopterin metabolism in senile dementia of Alzheimer type. J Neurol Neurosurg Psychiatry (1983) 1.15
The dendritic hypothesis for Alzheimer's disease pathophysiology. Brain Res Bull (2013) 1.14
Animal models in the drug discovery pipeline for Alzheimer's disease. Br J Pharmacol (2011) 1.13
Isl1 directly controls a cholinergic neuronal identity in the developing forebrain and spinal cord by forming cell type-specific complexes. PLoS Genet (2014) 1.12
Noninvasive brain stimulation in Alzheimer's disease: systematic review and perspectives for the future. Exp Gerontol (2011) 1.12
The LIM-homeobox gene Islet-1 is required for the development of restricted forebrain cholinergic neurons. J Neurosci (2008) 1.12
Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease. Br Med J (Clin Res Ed) (1981) 1.11
Impaired attention in the 3xTgAD mouse model of Alzheimer's disease: rescue by donepezil (Aricept). J Neurosci (2011) 1.11
Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders. Am J Neurodegener Dis (2013) 1.08
Dementia: biological solution still a long way off. Br Med J (Clin Res Ed) (1983) 1.08
Cholinergic forebrain degeneration in the APPswe/PS1DeltaE9 transgenic mouse. Neurobiol Dis (2007) 1.08
Expression of the low-affinity nerve growth factor receptor enhances beta-amyloid peptide toxicity. Proc Natl Acad Sci U S A (1994) 1.06
Amyloid precursor protein-induced axonopathies are independent of amyloid-beta peptides. Hum Mol Genet (2008) 1.06
Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J Biol Chem (2010) 1.04
Prior pathology in the basal forebrain cholinergic system predisposes to inflammation-induced working memory deficits: reconciling inflammatory and cholinergic hypotheses of delirium. J Neurosci (2012) 1.04
Parkinson's disease and Alzheimer's disease as disorders of the isodendritic core. Br Med J (Clin Res Ed) (1981) 1.03
Alzheimer's therapeutics: translation of preclinical science to clinical drug development. Neuropsychopharmacology (2011) 1.02
Alzheimer 100--highlights in the history of Alzheimer research. J Neural Transm (Vienna) (2006) 1.01
Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders. Mol Biosyst (2010) 1.01
Altered levels of acetylcholinesterase in Alzheimer plasma. PLoS One (2010) 0.99
The neurotrophins and their role in Alzheimer's disease. Curr Neuropharmacol (2011) 0.98
A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease. J Neurochem (2009) 0.98
Genetic risk factors in Alzheimer's disease. Mol Pathol (1998) 0.97
Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease. J Psychiatry Neurosci (1999) 0.97
Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease. Can J Psychiatry (2014) 0.97
Rivastigmine in the treatment of Alzheimer's disease: an update. Clin Interv Aging (2007) 0.97
Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits. Mol Cell Neurosci (2010) 0.97
Revisiting the Role of Acetylcholinesterase in Alzheimer's Disease: Cross-Talk with P-tau and β-Amyloid. Front Mol Neurosci (2011) 0.97
Acetylcholine receptors in dementia and mild cognitive impairment. Eur J Nucl Med Mol Imaging (2008) 0.96
Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology (Berl) (2005) 0.95
Activation of nicotinic acetylcholine receptor prevents the production of reactive oxygen species in fibrillar beta amyloid peptide (1-42)-stimulated microglia. Exp Mol Med (2008) 0.95
Non-steroidal anti-inflammatory drugs and cognitive function: are prostaglandins at the heart of cognitive impairment in dementia and delirium? J Neuroimmune Pharmacol (2011) 0.94
Cholinergic modulation of the medial prefrontal cortex: the role of nicotinic receptors in attention and regulation of neuronal activity. Front Neural Circuits (2014) 0.94
Comparative chemical profiling, cholinesterase inhibitions and anti-radicals properties of essential oils from Polygonum hydropiper L: A Preliminary anti- Alzheimer's study. Lipids Health Dis (2015) 0.93
Galanin fiber hyperinnervation preserves neuroprotective gene expression in cholinergic basal forebrain neurons in Alzheimer's disease. J Alzheimers Dis (2009) 0.92
Animal models of memory impairment. Philos Trans R Soc Lond B Biol Sci (1997) 0.92
Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. Brain (2009) 0.91
Sequence variation in the CHAT locus shows no association with late-onset Alzheimer's disease. Hum Genet (2003) 0.91
Cholinergic imbalance in the multiple sclerosis hippocampus. Acta Neuropathol (2011) 0.91
Cerebrovascular reactivity to carbon dioxide in Alzheimer's disease. J Alzheimers Dis (2013) 0.91
Activation of the metabotropic glutamate receptor attenuates N-methyl-D-aspartate neurotoxicity in cortical cultures. Proc Natl Acad Sci U S A (1991) 0.90
Subregional basal forebrain atrophy in Alzheimer's disease: a multicenter study. J Alzheimers Dis (2014) 0.90
Medial septal beta-amyloid 1-40 injections alter septo-hippocampal anatomy and function. Neurobiol Aging (2008) 0.90
Galanin hyperinnervation upregulates choline acetyltransferase expression in cholinergic basal forebrain neurons in Alzheimer's disease. Neurodegener Dis (2008) 0.89
In vivo MRI identifies cholinergic circuitry deficits in a Down syndrome model. Neurobiol Aging (2008) 0.89
In vivo visualization of donepezil binding in the brain of patients with Alzheimer's disease. Br J Clin Pharmacol (2007) 0.89
Postsynaptic Receptors for Amyloid-β Oligomers as Mediators of Neuronal Damage in Alzheimer's Disease. Front Physiol (2012) 0.89
Donepezil treatment restores the ability of estradiol to enhance cognitive performance in aged rats: evidence for the cholinergic basis of the critical period hypothesis. Horm Behav (2009) 0.89
Hippocampal plasticity during the progression of Alzheimer's disease. Neuroscience (2015) 0.89
Cholinergic system and constructional praxis: a further study of physostigmine in Alzheimer's disease. J Neurol Neurosurg Psychiatry (1984) 0.89
Transcranial magnetic stimulation in Alzheimer's disease: a neurophysiological marker of cortical hyperexcitability. J Neural Transm (Vienna) (2011) 0.89
In vitro screening for anti-cholinesterase and antioxidant activity of methanolic extracts of ayurvedic medicinal plants used for cognitive disorders. PLoS One (2014) 0.89
Cholinotrophic basal forebrain system alterations in 3xTg-AD transgenic mice. Neurobiol Dis (2010) 0.88
Heteroaromatic and aniline derivatives of piperidines as potent ligands for vesicular acetylcholine transporter. J Med Chem (2013) 0.88
Apolipoprotein E in the brain and its role in Alzheimer's disease. J Psychiatry Neurosci (1996) 0.88
Interaction of basal forebrain cholinergic neurons with the glucocorticoid system in stress regulation and cognitive impairment. Front Aging Neurosci (2015) 0.88
Advances in Alzheimer's disease drug development. BMC Med (2015) 0.88
Muscarinic acetylcholine receptor status in Alzheimer's disease assessed using (R, R) 123I-QNB SPECT. J Neurol (2007) 0.87
Senile plaques: staining for acetylcholinesterase and A4 protein: a comparative study in the hippocampus and entorhinal cortex. Acta Neuropathol (1990) 0.87
The genome sequence of Drosophila melanogaster. Science (2000) 74.32
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA (2000) 6.55
Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet (2000) 6.12
Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet (1993) 5.70
Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol (1988) 5.18
Role of contractile microfilaments in macrophage movement and endocytosis. Nat New Biol (1971) 4.82
Macrophages synthesis and release prostaglandins in response to inflammatory stimuli. Nature (1977) 4.75
A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci U S A (1990) 4.26
The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature (1999) 3.96
Regional organisation of neonatal intensive care in the North-west. Br Med J (1979) 3.50
A neuronal antigen in the brains of Alzheimer patients. Science (1986) 3.49
Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging (1992) 3.05
Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging (2005) 3.00
Asbestos induces selective release of lysosomal enzymes from mononuclear phagocytes. Nature (1974) 2.86
Regulation of prostaglandin synthesis and of the selective release of lysosomal hydrolases by mouse peritoneal macrophages. Biochem J (1978) 2.77
Changes in cellular enzyme levels and extracellular release of lysosomal acid hydrolases in macrophages exposed to group A streptococcal cell wall substance. J Exp Med (1974) 2.72
Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res (1997) 2.71
Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann Neurol (1994) 2.54
Dapsone in rheumatoid arthritis. Rheumatol Rehabil (1976) 2.45
Alzheimer's disease. A double-labeling immunohistochemical study of senile plaques. Am J Pathol (1988) 2.42
Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J Biol Chem (1992) 2.40
Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol Aging (2000) 2.40
The relative frequency of "dementia of unknown etiology" increases with age and is nearly 50% in nonagenarians. Arch Neurol (2000) 2.35
A systematic review of the role of human papillomavirus testing within a cervical screening programme. Health Technol Assess (1999) 2.32
Effects of gold, dapsone, and prednisone on serum C-reactive protein and haptoglobin and the erythrocyte sedimentation rate in rheumatoid arthritis. Ann Rheum Dis (1979) 2.30
Relation between initial blood pressure and its fall with treatment. Lancet (1985) 2.27
The role of arachidonic acid oxygenation products in pain and inflammation. Annu Rev Immunol (1984) 2.25
The Campbell Collaboration. Does for public policy what cochrane does for health. BMJ (2001) 2.24
The power of the classical twin study. Heredity (Edinb) (1978) 2.23
Hippocampal sclerosis: a common pathological feature of dementia in very old (> or = 80 years of age) humans. Acta Neuropathol (1994) 2.23
Communication disorders: planning a service to meet the needs. Br J Disord Commun (1989) 2.22
How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS) Rheumatology (Oxford) (2000) 2.21
Why don't patients turn up? Health Soc Serv J (1984) 2.20
Relationship between production and release of lymphocyte-activating factor (interleukin 1) by murine macrophages. 1. Effects of various agents. Cell Immunol (1981) 2.18
Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis (2002) 2.11
Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res (1979) 2.04
The biological effects of magnesium-leached chrysotile asbestos. Br J Exp Pathol (1977) 2.03
Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa. Nature (1980) 2.02
Mitotic mechanisms in Alzheimer's disease? J Cell Biol (1996) 2.00
A nucleated assembly mechanism of Alzheimer paired helical filaments. Proc Natl Acad Sci U S A (1998) 1.97
Recognition of tau epitopes by anti-neurofilament antibodies that bind to Alzheimer neurofibrillary tangles. Proc Natl Acad Sci U S A (1987) 1.96
Antigen-antibody complexes stimulate the synthesis and release of prostaglandins by mouse peritoneal macrophages. Prostaglandins (1979) 1.95
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol (2011) 1.93
Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer (2003) 1.90
Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging (1995) 1.90
Risking everything? Risk behavior, behavior change, and AIDS. Science (1994) 1.89
The inhibition of phagocytosis and facilitation of exocytosis in rabbit polymorphonuclear leukocytes by cytochalasin B. Lab Invest (1973) 1.89
The pulmonary vascular lesions of the adult respiratory distress syndrome. Am J Pathol (1983) 1.88
Ability of activated complement components to induce lysosomal enzyme release from macrophages. Nature (1976) 1.85
Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol Dis (2000) 1.84
Resting metabolic rate in homozygous sickle cell disease. Am J Clin Nutr (1993) 1.79
Senile dementia of the Alzheimer type without neocortical neurofibrillary tangles. J Neuropathol Exp Neurol (1987) 1.78
Significance of the individual components of the Apgar score. Br J Anaesth (1973) 1.76
Acute reactions to urographic contrast media. Br Med J (1975) 1.71
Mechanisms of endocytosis and exocytosis. Symp Soc Exp Biol (1974) 1.69
Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology (1991) 1.69
Paracetamol induced hepatotoxicity. Arch Dis Child (2006) 1.67
Chlamydia pneumoniae and asthma. Thorax (1998) 1.67
Is rheumatoid arthritis becoming less severe? J Chronic Dis (1983) 1.64
Immune complexes induce selective release of lysosomal hydrolases from macrophages. Nature (1974) 1.64
Connectivity of an effective hypothalamic surgical target for cluster headache. J Clin Neurosci (2007) 1.64
The Saccharomyces cerevisiae CCH1 gene is involved in calcium influx and mating. FEBS Lett (1997) 1.64
cAMP-dependent protein kinase phosphorylations on tau in Alzheimer's disease. J Neurosci (1999) 1.63
The diminished production of arachidonic acid oxygenation products by elicited mouse peritoneal macrophages: possible mechanisms. J Immunol (1980) 1.63
Alz 50, a monoclonal antibody to Alzheimer's disease antigen, cross-reacts with tau proteins from bovine and normal human brain. J Biol Chem (1988) 1.61
Pathogenesis of the chronic inflammatory lesion induced by group A streptococcal cell walls. Lab Invest (1974) 1.60
Purification and properties of filamin, and actin binding protein from chicken gizzard. J Biol Chem (1976) 1.60
Participation of mononuclear phagocytes in chronic inflammatory diseases. J Reticuloendothel Soc (1974) 1.59
CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology (2002) 1.58
Neurofibrillary tangles and senile plaques in aged bears. J Neuropathol Exp Neurol (1988) 1.56
Is there an energy deficiency in homozygous sickle cell disease? Am J Clin Nutr (1997) 1.54
The effect of continuous lumbar epidural analgesia on the acid-base status of maternal arterial blood during the first stage of labour. J Obstet Gynaecol Br Commonw (1973) 1.53
Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques. Acta Neuropathol (1989) 1.52
Cost implications of using an atraumatic dressing in the treatment of acute wounds. J Wound Care (2008) 1.51
Ballooned neurons in select neurodegenerative diseases contain phosphorylated neurofilament epitopes. Acta Neuropathol (1986) 1.50
Ophthalmoplegic migraine: the case for reclassification. Cephalalgia (2010) 1.50
Some aspects of the arterial response to venous occlusion in man. Clin Sci (Lond) (1983) 1.49
The effect of continuous lumbar epidural analgesia upon fetal acid-base status during the second stage of labour. J Obstet Gynaecol Br Commonw (1974) 1.49
Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol (2007) 1.48
A prospective, multicentre, observational cohort study of analgesia and outcome after pneumonectomy. Br J Anaesth (2011) 1.48
A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease. J Neurochem (1997) 1.47
Diffuse Lewy body disease. Neuropathological and biochemical studies of six patients. Acta Neuropathol (1987) 1.47
Outcome measurement in stroke rehabilitation research. Int Disabil Stud (1987) 1.46
Characterization of a neutral protease from lysosomes of rabbit polymorphonuclear leucocytes. Biochem J (1971) 1.45
Monoclonal antibodies to study the brain in schizophrenia. Brain Res (1989) 1.45
Alzheimer-related neuronal protein A68: specificity and distribution. Ann Neurol (1987) 1.45
A role for tissue transglutaminase in hepatic injury and fibrogenesis, and its regulation by NF-kappaB. Am J Physiol (1997) 1.44
Keratoconus and coexisting atopic disease. Br J Ophthalmol (1977) 1.44
The seasonal incidence of mania and its relationship to climatic variables. Psychol Med (1978) 1.43
Isolated liver transplant in infants with short bowel syndrome: insights into outcomes and prognostic factors. J Pediatr Gastroenterol Nutr (2009) 1.42
Detection of HLA-DR on microglia in the human brain is a function of both clinical and technical factors. Am J Pathol (1990) 1.40
Ultrastructure and biochemical composition of paired helical filaments in corticobasal degeneration. Am J Pathol (1994) 1.40
The relation between ease of forceps delivery and speed of cervical dilatation. Br J Obstet Gynaecol (1976) 1.40
Recording diastolic blood pressure in pregnancy. BMJ (1990) 1.40
Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia: the West Birmingham Stroke Project. Stroke (1998) 1.39
Alz-50 antibody recognizes Alzheimer-related neuronal changes. Ann Neurol (1988) 1.39
Calcium-activated potassium currents in mammalian neurons. Clin Exp Pharmacol Physiol (2000) 1.38
Cytochalasin B fails to inhibit pinocytosis by macrophages. Nat New Biol (1972) 1.38
Dynamic fetal cephalometry. Br J Obstet Gynaecol (1979) 1.38